Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma

Mao, Meng; Zaorsky, Nicholas G.; Jiang, Chao; Liao, Tian; Wang, Huan Huan; Liu, Chun Lei; Wang, Juan; Zhen, Tao; Sun, Yao; Wang, Jun; Pang, Qing; Zhao, Lu; Yuan, Zhi Yong; Wang, Ping

doi:10.1016/j.radonc.2013.01.008

Cited by 63 publications

(78 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surgery as part of the treatment should therefore be considered for all localized and regional GEP NEC patients with exceptions for esophageal primaries. Several small series confirm poor results after surgical treatment of esophageal NEC, especially for stage III disease where chemoradiation seems better [45,46]. The optimal therapy for localized disease, particularly in older patients with important comorbidities, remains an unanswered question.…”

Section: Surgerymentioning

confidence: 99%

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

et al. 2018

View full text Add to dashboard Cite

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are classified based on morphology and graded based on their proliferation rate as either well-differentiated low-grade (G1 to G2) neuroendocrine tumors (NET) or poorly differentiated high-grade (G3) neuroendocrine carcinomas (NEC). Recently, a new subgroup of well-differentiated high-grade pancreatic tumors (NET G3) has been defined. The GEP NEN G3 group consisting of both NEC and NET G3 has recently been shown to be a quite heterogeneous patient group concerning prognosis and treatment benefit, depending on factors such as the primary tumor site, differentiation, proliferation rate, and molecular alterations. In this review we discuss the existing data on diagnostics, treatment, and biomarkers in this patient group, the unmet needs, and the future perspectives.

show abstract

Section: Surgerymentioning

confidence: 99%

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…From a clinical standpoint, our data indicate that LS-C-SCEC has historically been treated similar to non-SCEC, in that S has been an integral treatment approach for LS-C-SCEC (76% of cases) and LS-SCEC. 8 Additionally, we note that patients with pure LS-SCEC have significantly improved OS compared with LS-C-SCEC. 8 The reason for this OS discrepancy is unclear and may be attributed to the fact that small cell carcinoma is typically more radiosensitive than non-SCEC or that the presence of a combined histology is secondary to multiple tumor cell lines.…”

Section: Survival (Probability)mentioning

confidence: 70%

“…4 Our previous study demonstrated that patients with pure LS-SCEC treated with RT+CT had an improved survival compared with those treated with S+CT. 8 We believe LS-C-SCEC is a unique disease, and its optimal management may be different than that of LS-SCEC. Therefore, we performed a retrospective study to evaluate the clinical features, optimal treatment strategy, and prognostic factors in patients with LS-C-SCEC.…”

mentioning

confidence: 97%

Multimodality Therapy Is Recommended for Limited-Stage Combined Small-Cell Esophageal Carcinoma

Meng

Wang

Zaorsky

et al. 2014

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Background and aim: Limited-stage combined small cell esophageal carcinoma (LS-C-SCEC) is a rare, poorly understood, underdiagnosed disease, with components of both small cell esophageal cancer and non-small cell esophageal cancer. We investigated the optimal treatment strategy and prognostic factors in patients with LS-C-SCEC. Patients and methods: LS-C-SCEC patients included in the analysis (from our hospital and the literature) were treated between January 1966 and December 2013. Patient treatment strategies included surgery (S), chemotherapy (CT), and radiation therapy (RT). The primary end point was overall survival (OS); the secondary end points included tumor complete response rates, patterns of failure, and toxicity. Kaplan-Meier curves were compared with the log-rank test. Univariate and multivariate analyses were used to determine prognosticators for OS.

show abstract

“…EC is generally treated with a combination of surgery, radiotherapy, and chemotherapy. However, the side effects of these therapies can be severe, resulting in poor patient compliance, discontinuation of therapy, and inadequate outcomes [5]. Therefore, improved treatment options are needed to achieve better clinical outcomes in patients with EC [6].…”

Section: Introductionmentioning

confidence: 99%

Identification of Herb Pairs in Esophageal Cancer

Cai¹,

Zhu²,

Niu³

et al. 2017

Complement Med Res

View full text Add to dashboard Cite

Background: Chinese herbal medicine (CHM) is used widely to treat various diseases, including cancer. However, effective herb pairs for treating specific cancer types have so far not been identified. Here, we aimed to calculate the survival benefits of herb pairs by cluster analysis, association rules, and survival evaluation in patients with esophageal cancer (EC) treated with CHM. Patients and Methods: 59 patients with EC who received 176 prescriptions including 178 types of herbs were enrolled into the study. The herb pairs were identified by both cluster analysis and association rules. Overall survival (OS) was estimated by the Kaplan-Meier method. Results: Eight groups of herb pairs were identified by cluster analysis, and 4 groups of herb pairs were identified by association rules. Of these, 3 groups of herb pairs were identified by both methods. OS estimation showed that the pair of chicken gizzard-membrane/Astragalus was associated with improved survival in patients with EC treated with CHM. Conclusion: Patients who received prescriptions containing the pair of chicken gizzard-membrane and Astragalus had improved OS compared with patients who received prescriptions lacking this pair.

show abstract

Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma

Cited by 63 publications

References 64 publications

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Multimodality Therapy Is Recommended for Limited-Stage Combined Small-Cell Esophageal Carcinoma

Identification of Herb Pairs in Esophageal Cancer

Contact Info

Product

Resources

About